So we began. Our first task was to establish a system to determine who would receive oral ribavirin and who would get the plasma according to the criteria laid out in our protocol. Everybody whose liver enzymes were above a certain critical level, which had been determined in our initial studies as indicative of a poor outcome, would receive one or the other treatment.
